title: [Perspectives of scintigraphic diagnosis of malignant lymphoma using a new radiopharmaceutical].
abstract: In the sequence of our studies on radiopharmaceuticals for malignant melanoma detection the results were most promising for the possible use of 125I or 123I-N-(2-diethyl amino ethyl)4-iodobenzamide. The biodistribution in mice bearing melanoma either human or animal from 4 to 24 hrs. post i.v. injection showed high uptake in tumor tissue together with relatively low uptake in muscle, brain, lung and liver. Scintigraphic images of the tumor obtained at the same times confirmed that melanoma detection was very promising.
authors: Unité I.N.S.E.R.M. 71, Clermont-Ferrand.
authors: G
authors: G
authors: Meyniel
authors: J
authors: J
authors: Michelot
authors: M F
authors: MF
authors: Moreau
authors: A
authors: A
authors: Veyre
mesh_terms: D000818:Animals; D001549:Benzamides / Q000493:pharmacokinetics; D003287:Contrast Media; D008545:Melanoma / Q000000981:diagnostic imaging*; D008722:Methods; D051379:Mice; D008810:Mice, Inbred C57BL; D008819:Mice, Nude; D011877:Radionuclide Imaging
chemical_list: D001549:Benzamides; D003287:Contrast Media; C066918:N-(2-(diethylamino)ethyl)-4-iodobenzamide
vernacular_title: Perspectives de diagnostic scintigraphique du mélanome malin par un nouveau radiopharmaceutique.